¼º¼®ÁÖ
¼Ò
¼Ó
: °³²Â÷º´¿ø
Àü¹®ºÐ¾ß : ºÎÀξÏ, ÀڱñÙÁ¾, ³¼ÒÁ¾¾ç,·Îº¿¼ö¼ú, º¹°°æ,Àڱðæ, ´ÜÀÏ°ø¼ö¼ú
Á÷
ˤ
: ±³¼ö
¸Þ
ÀÏ
:
.
Àü
È
:
02.3468.3000
ÆÑ
½º
:
02.558.1119
ÁÖ
¼Ò
:
¼¿ï½Ã °³²±¸ ¿ª»ï1µ¿ 650-9
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
134
ÇØ¿Ü
Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
133
±¹³»
Therapeutic outcomes of methotrexate injection in unruptured interstitial pregnancy.
132
ÇØ¿Ü
Management of Leimyosarcoma: A Survey Among Members of the Korean Gynecologic Oncology Group.
131
ÇØ¿Ü
Effect of menstrual phase on the surgical treatment of ovarian cysts.
130
ÇØ¿Ü
Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
129
ÇØ¿Ü
Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
128
ÇØ¿Ü
Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
127
ÇØ¿Ü
Recurrence of Ovarian Endometrioma in Adolescents after Conservative, Laparoscopic Cyst Enucleation.
126
ÇØ¿Ü
Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study.
125
±¹³»
Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729